HALO
Halozyme Therapeutics, Inc. (HALO)
Last Price$61.4(0.0%)
Market Cap$7,773.1M
22.4%
Peers median - 14.7%
46.1%
Peers median - (0.9%)
413.9%
Peers median - 8.2%
33.1%
Peers median - (11.1%)

Competing with HALO

Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name
Market Cap
Quality rating
Intrinsic value
1Y Return
Revenue
Free Cash Flow
Revenue growth
FCF margin
Gross margin
ROIC
Total Debt to Equity
$7,773.1M
7.6
$55.1
10.3% overvalued
49.1%
$1,015.3M
$468.4M
22.4%
46.1%
80.8%
33.1%
413.9%
$124.8B
5.7
$187.5
61.6% overvalued
17.8%
$11.0B
($790.3M)
11.5%
(7.2%)
86.1%
(15.0%)
10.7%
$77.0B
6.3
$1,048.3
46.0% undervalued
(25.4%)
$14.2B
$3,597.2M
8.3%
25.3%
84.5%
25.7%
5.7%
$34.4B
5.8
$123.0
78.8% overvalued
50.8%
$2,258.9M
($211.2M)
127.3%
(9.4%)
86.8%
(41.3%)
N/A
$30.7B
5.2
$91.8
61.6% overvalued
60.1%
$2,248.2M
($42.6M)
23.0%
(1.9%)
85.6%
(7.2%)
1,931.9%
$24.0B
5.9
$191.1
94.2% undervalued
2.2%
€2,751.1M
(€229.8M)
(28.0%)
(8.4%)
80.3%
(37.8%)
1.3%
$14.5B
5.4
$71.6
120.5% undervalued
11.2%
$2,263.9M
$2,769.0M
(3.8%)
122.3%
73.9%
14.5%
73.6%
$13.8B
7.7
$542.2
78.1% undervalued
22.0%
$2,877.4M
$1,080.6M
23.6%
37.6%
89.2%
65.4%
4.7%
$13.4B
6.7
$46.9
33.5% overvalued
(18.0%)
$2,850.5M
$475.4M
17.8%
16.7%
78.6%
11.0%
10.7%
$13.3B
5.9
$0.6
96.9% overvalued
330.2%
$0.0
($142.1M)
N/A
N/A
N/A
(3,335.4%)
1.9%
$1,846.9M
5.5
$2,745.6
1,111.0% undervalued
39.9%
$3,316.8M
($1,041.0M)
50.5%
(31.4%)
83.7%
(43.2%)
32.1%

Compare HALO Valuation Multiples with Peers

Compare HALO Valuation Multiples Dynamics with Peers

Crunching data... Almost there!

FAQ

1. How does Halozyme Therapeutics, Inc. (HALO) revenue growth compare to peers and the industry?

Halozyme Therapeutics, Inc. (HALO) revenue growth is 22.4%, compared to the peers' median of 14.7%.

2. How does Halozyme Therapeutics, Inc. (HALO) Free Cash Flow (FCF) margin compare to peers and the industry?

Halozyme Therapeutics, Inc. (HALO) FCF margin is 46.1%, compared to the peers' median of (0.9%).

4. How does Halozyme Therapeutics, Inc. (HALO) ROIC (Return on Invested Capital) compare to peers and the industry?

Halozyme Therapeutics, Inc. (HALO) ROIC is 33.1%, compared to the peers' median of (11.1%).